ArticleClinical kidney journal2026
Baseline hematuria in autosomal dominant polycystic kidney disease.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hematuria is common in autosomal dominant polycystic kidney disease (ADPKD), but whether baseline hematuria predicts long-term kidney outcomes is unknown. We tested its association with kidney function decline, renal survival, and volume growth. Methods: In a single-center ADPKD cohort, 175 patients had standardized urinary sediment assessment in a baseline period (2006-11); 173 (99%) were linked to a registry (follow-up up to 20 years). Microscopic hematuria was >5 erythrocytes per high-power field; macroscopic was from clinical history. Outcomes were the estimated glomerular filtration rate (eGFR) slope, a composite of end-stage kidney disease or eGFR halving, and total kidney volume (TKV) growth, adjusted for baseline eGFR, age, and sex. Results: Baseline hematuria was present in 45 patients (26%; microscopic 15%, macroscopic 17%) and was associated with faster adjusted eGFR decline [mixed-model differential slope: any -1.46 ml/min/1.73 m²/year (95% confidence interval {CI}, -2.12 to -0.80); macroscopic -1.73 (-2.53 to -0.93); microscopic -1.53 (-2.34 to -0.73); Conclusions: Baseline hematuria-particularly macroscopic and non-infection-associated microscopic-independently predicts accelerated functional decline and worse renal survival. Because this prognostic signal is functional rather than volume-driven, this simple, routinely available finding may complement imaging-based risk markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.